Anaplastic large cell lymphoma
Revision as of 23:54, 26 November 2014 by Jwarner (talk | contribs) (Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' Is th...")
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Relapsed/refractory
Brentuximab vedotin (Adcetris)
Regimen, Pro et al. 2012
Phase II
- Brentuximab vedotin (Adcetris) 1.8 mg/kg IV over 30 minutes on day 1
3-week cycles up to 16 infusions
References
- Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012 Jun 20;30(18):2190-6. Epub 2012 May 21. link to original article contains verified protocol PubMed